A new study has traced the evolution of the hepatitis B virus (HBV) from prehistory to the present, revealing dissemination routes and changes in viral diversity.
In a new paper in the journal Science, researchers uncover the evolution of HBV since the Early Holocene (roughly 12,000 years ago, when the human species began to dominate the globe) by analysing the largest dataset of ancient viral genomes produced to date.
Continue reading “The Prehistory of Hepatitis B”
Australia still has a long way to go to achieve its National Hepatitis B Strategy targets aimed at eliminating the disease by 2030.
Continue reading “Hepatitis B Targets – Australia 23 years behind on care, 24 on treatment”
Action needed now to eliminate viral hepatitis in the next 10 years
We live in a world built upon achievements. We have travelled to the moon, developed vaccines, created the internet and even cloned life itself. Today we have the opportunity to create our next greatest achievement: the elimination of viral hepatitis. The journey has already started.
Continue reading “The 2030 Accord”
In a rare alignment, the Australian 2021 World Hepatitis Day campaign is adopting the message of the global campaign. This year, both global and national campaigns are telling you: hepatitis can’t wait.
The COVID-19 pandemic has seen a common outcome in one aspect of healthcare – people with minor or chronic illnesses putting off seeing their healthcare providers. Unfortunately, for some conditions, there can be dire consequences if you wait. Hepatitis is one of those.
Continue reading “Hep Can’t What?”
There is a common view that once you start hepatitis B treatment, you will be on it for life. This is changing. In recent years, numerous studies have been done looking into the notion of functional cure for hepatitis B which, when achieved, means therapy can be stopped.
Continue reading “Hepatitis B Treatment—not necessarily a life-long commitment”
The Australian Government has used the delayed 2020 Federal Budget to commit to funding for several vital areas of hepatitis research, including pathogen genomics, prison-based interventions, and point-of-care testing. However, Australia’s hepatitis community has a right to view this commitment with some scepticism.
Continue reading “Release Hep Funds to Meet Targets”